



## **Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021**

**HOUSTON – March 3, 2021** – Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, March 10, 2021 at 8:30 a.m. ET to report financial results for the year ended December 31, 2020 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 6296959. A live audio webcast of the call will also be available on the Presentations section of the Company's website, [www.biopathholdings.com](http://www.biopathholdings.com). An archived webcast will be available on the Bio-Path website approximately two hours after the event.

### **About Bio-Path Holdings, Inc.**

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies. For more information, please visit the Company's website at <http://www.biopathholdings.com>.

###

### **Contact Information:**

#### **Investors**

Will O'Connor  
Stern Investor Relations  
212-362-1200  
[will@sternir.com](mailto:will@sternir.com)

Doug Morris

Investor Relations  
Bio-Path Holdings, Inc.  
832-742-1369